Skip to main content
. Author manuscript; available in PMC: 2019 Dec 1.
Published in final edited form as: Cancer Prev Res (Phila). 2018 Oct 16;11(12):779–788. doi: 10.1158/1940-6207.CAPR-17-0396

Table 1:

Characteristics of current users and nonusers of lipid-lowering medications, men in ARIC at visit 4 (1996 – 1999)

All men Black men White men



Current lipid-lowering drug use at visit 4 (1996–1999)

No Yes No Yes No Yes

N 3,934 953 836 105 3,098 848
Age (years) 63 64 62 63 63 64
Black (%) 21.3 11.0 - - - -
Education (%)
 Less than high school graduate 20.2 17.3 37.8 34.3 15.4 15.2
 High school graduate, vocational school, some college 36.9 38.0 26.7 24.8 39.7 39.6
 College graduate, some graduate school, graduate degree 42.7 44.5 35.2 40.0 44.8 45.1
 Missing 0.2 0.2 0.3 0.9 0.1 0.1
Height (cm) 176 175 176 176 176 175
BMI (kg/m2) 28.4 29 28.3 29.9 28.4 28.9
Waist-to-hip ratio 0.98 0.99 0.96 0.97 0.98 0.99
Cigarette smoking status (%)
 Never 31.9 25.5 30.7 33.3 32.2 24.5
 Former/quit ≥10 years ago 39.0 48.6 29.2 38.1 41.6 49.9
 Current/quit <10 years ago 29.1 25.9 40.1 28.6 26.2 25.6
Diabetes status (%)
 No 43.9 35.2 40.9 23.8 44.6 36.5
 At risk for diabetes 39.4 39.3 36.1 40.0 40.3 39.3
 Undiagnosed diabetes 5.1 4.9 6.7 1.9 4.7 5.3
 Diabetes 11.6 20.6 16.3 34.3 10.4 18.9
Ever hypertensive (%) 49.8 66.0 69.0 85.7 44.6 63.6
Ever elevated cholesterol (%) 25.4 54.9 30.3 65.7 24.1 53.5
Baseline health insurance (%) 92.4 95.9 78.8 83.8 96.0 97.4
*

- Values are means or percentages. All characteristics are assessed at visit 4, unless otherwise indicated. Visit 4 was chosen because by this point statins had been on the market for several years and 76% of the lipid-lowering medications used by ARIC participants were statins.